Table 2 Primary and secondary outcomes of the study: incidence and severity of AKI, incidence of AKD and CKD, and incidence of nausea and vomiting.
Total (n = 295) | PPIs group (n = 145) | Non-PPIs group (n = 150) | P | |
|---|---|---|---|---|
Primary outcome | ||||
Incidence of AKI, n (%) | 40 (13.6) | 28 (19.3) | 12 (8.0) | 0.005 |
Severity of AKI, n (%) | 0.005 | |||
1 | 38 (12.9) | 27 (18.6) | 11 (7.3) | |
2 | 2 (0.7) | 1 (0.7) | 1 (0.7) | |
3 | 0 | 0 | 0 | |
Secondary outcome | ||||
Incidence of AKD, n (%) | 12 (4.1) | 8 (5.5) | 4 (2.7) | 0.215 |
Incidence of CKD, n (%) | 7 (2.4) | 4 (2.8) | 3 (2.0) | 0.964 |
Gastrointestinal toxicity | ||||
Nausea | 0.029 | |||
Grade 1–2, n (%) | 151 (51.2) | 66 (45.5) | 85 (56.7) | |
Grade 3–4, n (%) | 6 (2.0) | 2(1.4) | 4 (2.7) | |
Vomiting | 0.140 | |||
Grade 1–2, n (%) | 112 (40.0) | 50 (34.5) | 62 (41.3) | |
Grade 3–4, n (%) | 6 (2.0) | 2 (1.4) | 4 (2.7) | |
